Last Price
11.97
Today's Change
+1.47 (14.00%)
Day's Change
10.80 - 12.38
Trading Volume
10,088,687
Market Cap
3 Billion
Shares Outstanding
296 Million
Avg Volume
2,560,523
Avg Price (50 Days)
11.11
Avg Price (200 Days)
11.24
PE Ratio
-30.69
EPS
-0.39
Earnings Announcement
06-Nov-2024
Previous Close
10.50
Open
10.82
Day's Range
10.8 - 12.38
Year Range
9.02 - 14.57
Trading Volume
10,184,206
1 Day Change
14.00%
5 Day Change
19.34%
1 Month Change
6.88%
3 Month Change
12.92%
6 Month Change
13.46%
Ytd Change
-15.94%
1 Year Change
11.04%
3 Year Change
11.87%
5 Year Change
46.33%
10 Year Change
113.37%
Max Change
-17.05%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.